FONR.NASDAQFonar CORP

8-K: FONAR Reports Decreased Income Despite Increased MRI Scan Volume at Managed Sites

Sentiment:

Earnings Release


FONAR Corporation announces its financial results for the second quarter and six-month period of fiscal year 2025, revealing a decrease in net income despite an increase in MRI scan volume at HMCA managed sites.

Worse than expectedThe document contains worse than expected results due to decreases in total revenues, income from operations, net income, and diluted net income per common share.

Summary

  • FONAR Corporation reported its financial results for the six-month period and second quarter of fiscal year 2025, which ended on December 31, 2024.
  • MRI scan volume at HMCA managed sites increased by 7% to 79,207 scans during the six-month period, while scan volume at HMCA owned sites decreased by 4% to 26,961 scans.
  • Cash and cash equivalents and short-term investments decreased by 5% to $53.7 million.
  • Total revenues decreased by 3% to $49.9 million for the six-month period and by 2% to $25.0 million for the quarter.
  • Income from operations decreased by 38% to $7.2 million for the six-month period and by 48% to $2.6 million for the quarter.
  • Net income decreased by 36% to $6.4 million for the six-month period and by 48% to $2.4 million for the quarter.
  • Diluted net income per common share decreased by 33% to $0.75 for the six-month period and by 44% to $0.30 for the quarter.
  • Net book value per common share increased to $25.66 per share.
  • Selling, general, and administrative expenses (SG&A) increased by 24% for the quarter and 16% for the six-month period, due to a reserve against accounts receivables from American Transit Insurance Company and a new outside billing contract.
  • Operating cash flow decreased by 42% to $3.9 million for the six-month period.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's positive growth in MRI scan volume at managed sites, the overall financial performance shows declines in revenue and income, offset by a stock repurchase program.

Positives

  • MRI scan volume at HMCA managed sites increased by 7% during the six-month period.
  • Net book value per common share increased to $25.66 per share.
  • Working capital increased 2% to $125.4 million at December 31, 2024.
  • The ratio of Total Assets / Total Liabilities at December 31, 2024, was 4.2 as compared to 3.7 at June 30, 2024.

Negatives

  • MRI scan volume at HMCA owned sites decreased by 4% during the six-month period.
  • Total revenues decreased by 3% for the six-month period.
  • Income from operations decreased by 38% for the six-month period.
  • Net income decreased by 36% for the six-month period.
  • Diluted net income per common share decreased by 33% for the six-month period.
  • Cash and cash equivalents and short-term investments decreased by 5%.
  • Operating cash flow decreased by 42% for the six-month period.
  • Selling, general, and administrative expenses (SG&A) increased by 16% for the six-month period.

Risks

  • A significant reserve against accounts receivables is attributable to American Transit Insurance Company, which has indicated it is approaching insolvency.
  • Increased selling, general, and administrative expenses due to a new outside billing contract.
  • The company is limited by restrictions in its share repurchases under Rule 10b-18.

Future Outlook

Scan volume for the balance of Fiscal 2025 looks promising due to the addition of high-field MRIs at two existing HMCA-managed scanning centers in Nassau County, New York.

Management Comments

  • Timothy Damadian, president and CEO of FONAR, said the total second-quarter scan volume in Fiscal 2025 at HMCA-managed MRI centers was slightly more (0.11%) than that of the previous quarter and 1,868 more (3.65%) than that of the second-quarter of 2024.
  • Mr. Damadian concluded, 'I remain grateful for our management team and all the FONAR and HMCA employees whose hard work and commitment continue to make the Company successful.'

Industry Context

The announcement reflects the competitive landscape of the medical imaging industry, where companies are focused on expanding their MRI services and improving diagnostic capabilities. The addition of high-field MRIs at existing centers indicates a strategic move to enhance service offerings and attract more patients.

Comparison to Industry Standards

  • It is difficult to compare FONAR's results directly to industry standards without specific competitor data for the same period.
  • However, companies like Siemens Healthineers, GE Healthcare, and Philips Healthcare are major players in the MRI market.
  • These larger companies typically have more diversified revenue streams and global operations, making direct comparisons challenging.
  • FONAR's focus on its UPRIGHT MRI and HMCA managed sites differentiates it from these larger competitors.

Related Party Transactions

  • Service and repair fees related parties are mentioned in the income statement.
  • Management and other fees related medical practices are mentioned in the income statement.
  • Investment income related party is mentioned in the income statement.
  • Other income related party is mentioned in the income statement.
  • Accounts receivable related party is mentioned in the balance sheet.
  • Note receivable related party is mentioned in the balance sheet.
  • Due to related party medical practices is mentioned in the balance sheet.
  • Unearned revenue on service contracts related party is mentioned in the balance sheet.
  • Gain on sale of equipment related party is mentioned in the cash flow statement.

Stakeholder Impact

  • Shareholders may be concerned about the decreased revenues and income.
  • Employees at HMCA managed sites may benefit from increased scan volumes.
  • Customers may benefit from the addition of high-field MRIs at HMCA-managed scanning centers.

Next Steps

  • The company will continue to seek to establish new locations or acquire centers to enhance existing networks and increase profitability.
  • The company anticipates the addition of high-field MRIs at two existing HMCA-managed scanning centers in Nassau County, New York.

Key Dates

DateDescription
1974Dr. Damadian's original patent was granted, leading to the creation of Indomitable and all commercial MRI scanners.
1978FONAR was incorporated.
1980FONAR sold the world's first commercial MRI to Ronald J. Ross, MD.
January 1981Dr. Ross and his team began the world's first clinical MRI trials.
1981FONAR went public (Nasdaq:FONR).
April 25, 2001Raymond V. Damadian, M.D., was awarded the Lemelson-MIT Lifetime Achievement Award.
September 13, 2022FONAR announced a stock repurchase plan of up to $9 million.
December 31, 2023Comparative period for financial results.
June 30, 2024Comparative period for balance sheet items.
December 31, 2024End of the reported second fiscal quarter of 2025.
February 18, 2025Date of the press release announcing the financial results.
February 19, 2025Date of report signature.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.